Abstract
Purpose
The purpose of the study was to determine factors correlated with the progression of irreversible visual disturbance in Behcet's disease (BD) with ocular involvement.
Methods
Forty-seven BD patients with ocular inflammation, who presented with the first ocular episode, and who had been followed continuously for 5–10 years in our hospital, were studied. Charts were reviewed for gender, onset age of uveitis, complete or incomplete type BD, HLA-B51 status, final visual acuity at the last remission period, mean number of ocular attacks per year, and clinical findings of iridocyclitis with profuse hypopyon, strong vitreous opacity blocking the observation of retinal vessels, diffuse retinal vasculitis, and exudates with hemorrhage within the retinal vascular arcade.
Results
Patients with a visual acuity of ≤20/200 and those with >20/200 differed significantly in the mean number of ocular attacks per year and clinical findings of strong vitreous opacity and exudates within the retinal vascular arcade, but not with regard to the other factors. In addition, the frequency of ocular attacks showed a significant negative correlation with the outcome of visual acuity. Logistic regression analysis indicated a significant association of an average of more than three ocular attacks per year, strong vitreous opacity, and exudates within the retinal vascular arcade with poor visual outcome.
Conclusions
This study indicates that more than three ocular attacks per year, strong vitreous opacity, and exudates within the retinal vascular arcade are the risk and prognostic factors for a poor outcome of visual acuity in BD patients.
Similar content being viewed by others
References
Barra C, Belfort Junior R, Abreu MT, Kim MK, Martins MC, Petrilli AM (1991) Behcet's disease in Brazil—a review of 49 cases with emphasis on ophthalmic manifestations. Jpn J Ophthalmol 35:339–346
Benezra D, Cohen E (1986) Treatment and visual prognosis in Behcet's disease. Br J Ophthalmol 70:589–592
Chajek T, Fainaru M (1975) Behcet's disease. Report of 41 cases and a review of the literature. Medicine (Baltimore) 54:179–196
Chung YM, Liu JH, Tsi ST (1986) Behcet's disease in Taiwan—a review of 53 cases. Jpn J Ophthalmol 30:318–323
De Smet MD, Bitar G, Mainigi S, Nussenblatt RB (2001) Human S-antigen determinant recognition in uveitis. Investig Ophthalmol Vis Sci 42:3233–3238
Demiroglu H, Barista I, Dundar S (1997) Risk factor assessment and prognosis of eye involvement in Behcet's disease in Turkey. Ophthalmology 104:701–705
Er H, Evereklioglu C, Cumurcu T, Turkoz Y, Ozerol E, Sahin K, Doganay S (2002) Serum homocysteine level is increased and correlated with endothelin-1 and nitric oxide in Behcet's disease. Br J Ophthalmol 86:653–657
Ermakova NA, Alekberova ZS, Prokaeva TB (2003) Autoimmunity to S-antigen and retinal vasculitis in patients with Behcet's disease. Adv Exp Med Biol 528:279–281
Evereklioglu C, Er H, Turkoz Y, Cekmen M (2002) Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcet's disease. Mediat Inflamm 11:87–93
France R, Buchanan RN, Wilson MW, Sheldon MB Jr (1951) Relapsing iritis with recurrent ulcers of the mouth and genitalia (Behcet's syndrome); review: with report of additional case. Medicine (Baltimore) 30:335–355
Hamza M, Elleuch M, Slim A, Hamzaoui K, Ayed K (1990) Antibodies to Herpes simplex virus in patients with Behcet's disease. Clin Rheumatol 9:498–500
Kazokoglu H, Saatci O, Cuhadaroglu H, Eldem B (1991) Long-term effects of cyclophosphamide and colchicine treatment in Behcet's disease. Ann Ophthalmol 23:148–151
Kotter I, Zierhut M, Eckstein AK, Vonthein R, Ness T, Gunaydin I, Grimbacher B, Blaschke S, Meyer-Riemann W, Peter HH, Stubiger N (2003) Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87:423–431
Lehner T, Stanford MR, Phipps PA, Sun JB, Xiao BG, Holmgren J, Shinnick T, Hasan A, Mizushima Y (2003) Immunopathogenesis and prevention of uveitis with the Behcet's disease-specific peptide linked to cholera toxin B. Adv Exp Med Biol 528:173–180
Martin DK, Nelms DC, Mackler BF, Peavy DL (1979) Lymphoproliferative responses induced by streptococcal antigens in recurrent aphthous stomatitis and Behcet's syndrome. Clin Immunol Immunopathol 13:146–155
Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G (1989) Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet I:1093–1096
Mishima S, Masuda K, Izawa Y, Mochizuki M, Namba K (1979) The eighth Frederick H. Verhoeff lecture presented by Saiichi Mishima, MD. Behcet's disease in Japan: ophthalmologic aspects. Trans Am Ophthalmol Soc 77:225–279
Mizushima Y, Matsumura N, Mori M, Shimizu T, Fukushima B, Mimura Y, Saito K, Sugiura S (1977) Colchicine in Behcet's disease. Lancet II:1037
Mizushima Y (1988) Revised diagnostic criteria for Behcet's disease in 1987. Ryumachi 28:66–70
Mor F, Weinberger A, Cohen IR (2002) Identification of alpha-tropomyosin as a target self-antigen in Behcet's syndrome. Eur J Immunol 32:356–365
Niwa Y, Miyake S, Sakane T, Shingu M, Yokoyama M (1982) Auto-oxidative damage in Behcet's disease—endothelial cell damage following the elevated oxygen radicals generated by stimulated neutrophils. Clin Exp Immunol 49:247–255
Nussenblatt RB, Palestine AG, Chan CC, Mochizuki M, Yancey K (1985) Effectiveness of cyclosporin therapy for Behcet's disease. Arthritis Rheum 28:671–679
Pivetti Pezzi P, Gasparri V, De Liso P, Catarinelli G (1985) Prognosis in Behcet's disease. Ann Ophthalmol 17:20–25
Reimold AM (2002) TNF-alpha as therapeutic target: new drugs, more applications. Curr Drug Targets Inflamm Allergy 1:377–392
Sakamoto M, Akazawa K, Nishioka Y, Sanui H, Inomata H, Nose Y (1995) Prognostic factors of vision in patients with Behcet disease. Ophthalmology 102:317–321
Sakane T, Takeno M, Suzuki N, Inaba G (1999) Behcet's disease. N Engl J Med 341:1284–1291
Sancak B, Onder M, Oztas MO, Bukan N, Gurer MA (2003) Nitric oxide levels in Behcet's disease. J Eur Acad Dermatol Venereol 17:7–9
Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN (2001) Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 358:295–296
Tessler HH, Jennings T (1990) High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behcet's disease. Br J Ophthalmol 74:353–357
Triolo G, Vadala M, Accardo-Palumbo A, Ferrante A, Ciccia F, Giardina E, Citarrella P, Lodato G, Licata G (2002) Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behcet's disease. Ann Rheum Dis 61:560–561
Wechsler B, Bodaghi B, Huong DL, Fardeau C, Amoura Z, Cassoux N, Piette JC, LeHoang P (2000) Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behcet's disease. Ocul Immunol Inflamm 8:293–301
Wong RC, Ellis CN, Diaz LA (1984) Behcet's disease. Int J Dermatol 23:25–32
Yoshida A, Kawashima H, Motoyama Y, Shibui H, Kaburaki T, Shimizu K, Ando K, Hijikata K, Izawa Y, Hayashi K, Numaga J, Fujino Y, Masuda K, Araie M (2004) Comparison of patients with Behcet's disease in the 1980s and 1990s. Ophthalmology 111:810–815
Acknowledgements
This work was supported by Grant-in-Aid 16591769 for Scientific Research from the Japan Society for the Promotion of Science.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Takeuchi, M., Hokama, H., Tsukahara, R. et al. Risk and prognostic factors of poor visual outcome in Behcet's disease with ocular involvement. Graefe's Arch Clin Exp Ophthalmo 243, 1147–1152 (2005). https://doi.org/10.1007/s00417-005-0005-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-005-0005-8